MannKind posts transcript of nintedanib DPI Phase 1b results call

• MannKind hosted a July 29, 2026 call on Phase 1b INFLO-1 results for nintedanib DPI in IPF, led by CEO Michael Castagna and SVP Respiratory Wassim Fares.
• INFLO-1 enrolled 27 IPF patients at 10 U.S. sites; management highlighted no serious adverse events, no GI events, no discontinuations, no dose reductions.
• Fares: ~60% of active patients reported no cough adverse event; ~90% had no cough or Grade 1 cough; 30% mild, 10% moderate, mostly transient.
• Castagna: nintedanib DPI plasma Cmax ran ~6-8x higher than published nebulized nintedanib at comparable doses; oral PK not replicated in humans.
• INFLO-2 global Phase 2 underway: 210 IPF patients, 12-week placebo-controlled period, 24-week open-label extension; primary safety/tolerability, FVC key endpoint.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief on July 31, 2026, and is solely responsible for the information contained therein.